CHSY3

CHSY3 is a type II membrane glycosyltransferase that drives elongation of chondroitin sulfate (CS) chains, providing the catalytic core of the CS polymerization machinery (PMID:12907687, PMID:41298522). It is bifunctional, carrying an N-terminal GT31-like domain that transfers β1,3-glucuronic acid and a C-terminal GT7-like domain that transfers β1,4-N-acetylgalactosamine, separated by a cystatin-like linker, thereby building the alternating GlcUAβ1-3GalNAc/GalNAcβ1-4GlcUA disaccharide repeat at the nonreducing terminus (PMID:12907687, PMID:41298522, PMID:42204168). CHSY3 alone cannot polymerize chondroitin; processive chain extension requires its assembly into heterodimeric complexes with partner proteins ChSy-1, CHPF, or CHPF2, and complex formation alone is insufficient because catalytic activity of CHSY3 itself is obligatory — a binding-competent but catalytically dead mutant fails to support polymerization (PMID:17253960, PMID:18316376). Cryo-EM structures of CHSY3-CHPF and CHSY3-CHPF1 heterodimers establish that CHSY3 supplies all catalytic activity while the CHPF subunit serves a stabilizing structural role (PMID:41298522, PMID:42204168). Physiologically, CHSY3-dependent CS biosynthesis maintains nucleus pulposus homeostasis: its loss in mice causes spontaneous intervertebral disc degeneration through reduced YAP1 activation via actin tension (PMID:33089528), and CHSY3 is required for the protective anti-degenerative effect of low-dose celecoxib (PMID:36864461). In choriocarcinoma cells, CHSY3 sustains placental-type CS-A production that supports proliferation, invasion, and tumorigenesis (PMID:33390789).

1. 2003 High

   Established that CHSY3 is an enzyme with dual transferase activities acting on CS chains, defining its biochemical identity but also revealing it cannot work alone.

   Evidence Recombinant enzyme expression in COS-7 cells with in vitro glycosyltransferase assays on chondroitin/CS acceptors

   PMID:12907687

   Open questions at the time

   • Did not explain how polymerization is achieved when the enzyme cannot polymerize alone
   • No structural basis for the two activities
2. 2007 High

   Resolved why CHSY3 cannot polymerize alone by showing it must physically partner with ChSy-1 or ChPF to acquire polymerization activity, and confirmed cellular relevance via knockdown/overexpression.

   Evidence Pull-down assays, co-expression activity reconstitution, RNAi and overexpression with CS quantification in HeLa cells

   PMID:17253960

   Open questions at the time

   • Stoichiometry and architecture of the complexes unknown
   • Relative catalytic contribution of each subunit unresolved
3. 2008 High

   Demonstrated that CHSY3's own catalytic activity, not merely its presence in a complex, is required for polymerization, separating the binding and catalytic functions of complex members.

   Evidence Co-expression with catalytically inactive mutant analysis and in vitro polymerization on linkage-region tetrasaccharide acceptor, plus RNAi/overexpression in HeLa cells

   PMID:18316376

   Open questions at the time

   • Mechanism of how partners enable processivity unknown
   • No structural model of the active complex
4. 2020 Medium

   Connected CHSY3 enzymatic function to an in vivo physiological role, showing CS biosynthesis maintains intervertebral disc homeostasis through actin-tension-mediated YAP1 signaling.

   Evidence CRISPR-Cas9 knockout mouse, RNA-seq, pathway analysis, and functional assays in nucleus pulposus cells

   PMID:33089528

   Open questions at the time

   • Single lab
   • Direct mechanistic link from CS loss to actin tension not fully defined
5. 2021 Medium

   Extended CHSY3's role beyond cartilage/disc biology, implicating it in placental-type CS-A production that supports tumor cell proliferation and metastasis.

   Evidence CRISPR/Cas9 knockout in JEG3 choriocarcinoma cells with in vitro phenotypic assays and xenograft models

   PMID:33390789

   Open questions at the time

   • Single lab
   • Molecular pathway downstream of pl-CSA loss not defined
6. 2023 Medium

   Placed CHSY3 epistatically downstream of a therapeutic intervention, showing it is required for celecoxib-mediated protection against disc degeneration.

   Evidence Genetic epistasis with CHSY3 knockout mice in a lumbar instability IDD model with celecoxib delivery

   PMID:36864461

   Open questions at the time

   • Mechanism linking celecoxib to CHSY3 upregulation unknown
   • Single lab
7. 2025 High

   Provided the structural basis for CHSY3-driven polymerization, showing it carries GT31 and GT7 domains contributing all catalysis while CHPF/CHPF2 stabilize the complex.

   Evidence Cryo-EM of CHSY3-CHPF complex with mutational analysis, in vitro glycosylation on fluorescent substrates, and in cellulo complementation

   PMID:41298522

   Open questions at the time

   • Processive vs. distributive mechanism still under definition
   • How four distinct heterodimers achieve different chain lengths unresolved
8. 2026 High

   Independently confirmed the CHSY3-CHPF1 domain architecture and the catalytic division of labor, solidifying CHSY3 as the sole catalytic subunit.

   Evidence Cryo-EM of CHSY3-CHPF1 heterodimer, structural modeling, and catalytic mutant enzymatic analysis

   PMID:42204168

   Open questions at the time

   • Full polymerization elongation cycle not captured structurally
   • Regulation of complex assembly in vivo unknown

• How CHSY3 complex assembly and CS chain-length output are regulated in different tissues, and the precise route from CS loss to YAP1/actin-tension signaling, remain open.
• No in vivo data on which partner CHSY3 uses in each tissue
• Direct biochemical link between CS and actin/YAP signaling not established